Question 1

Leukoreduction filters are used in the transfusion of red blood cells and platelets to prevent:

Accepted Answer

A)  nonfebrile hemolytic transfusion reactions. 
B)  febrile hemolytic transfusion reactions. 
C)  febrile nonhemolytic transfusion reactions. 
D)  nonfebrile nonhemolytic transfusion reactions. 
A)  nonfebrile hemolytic transfusion reactions. 
B)  febrile hemolytic transfusion reactions. 
C)  febrile nonhemolytic transfusion reactions. 
D)  nonfebrile nonhemolytic transfusion reactions.

Question 2

Oncology patients usually receive repeated red blood cell and platelet transfusions because of:

Accepted Answer

A)  radiation therapy. 
B)  tumor infiltration of bone marrow. 
C)  chemotherapy. 
D)  all of the above. 
A)  radiation therapy. 
B)  tumor infiltration of bone marrow. 
C)  chemotherapy. 
D)  all of the above.

Question 3

Why are fresh blood units (less than 7 days old) preferred for a neonate transfusion?

Accepted Answer

A)  They reduce the risk of hyperkalemia. 
B)  They minimize 2,3 DPG levels. 
C)  They reduce the risk of hypokalemia. 
D)  They reduce the risk of hypernatremia. 
A)  They reduce the risk of hyperkalemia. 
B)  They minimize 2,3 DPG levels. 
C)  They reduce the risk of hypokalemia. 
D)  They reduce the risk of hypernatremia.

Question 4

How does 25% albumin induce diuresis in liver disease patients?

Accepted Answer

A)  Albumin inactivates antidiuretic hormone in diabetics. 
B)  Albumin solution acts with diuretic drugs to concentrate plasma driving water into extravascular spaces. 
C)  Albumin solution acts with diuretics and brings extravascular water into vascular space to dilute albumin. 
D)  None of the above 
A)  Albumin inactivates antidiuretic hormone in diabetics. 
B)  Albumin solution acts with diuretic drugs to concentrate plasma driving water into extravascular spaces. 
C)  Albumin solution acts with diuretics and brings extravascular water into vascular space to dilute albumin. 
D)  None of the above

Question 5

Which of the following methods provides the purest factor VIII concentrates?

Accepted Answer

A)  Anion exchange chromatography 
B)  Monoclonal antibody purification 
C)  DNA technology 
D)  Pasteurization 
A)  Anion exchange chromatography 
B)  Monoclonal antibody purification 
C)  DNA technology 
D)  Pasteurization

Question 6

All coagulation factors are produced in the liver except:

Accepted Answer

A)  antihemophilic factor (AHF). 
B)  factor I. 
C)  vWF. 
D)  factor VII. 
A)  antihemophilic factor (AHF). 
B)  factor I. 
C)  vWF. 
D)  factor VII.

Question 7

What is the source of hyperimmune globulins used in the prevention of hepatitis B?

Accepted Answer

A)  Recombinant hepatitis B purified protein 
B)  Plasma donors whose sera are devoid of hepatitis B antibody 
C)  Plasma donors whose sera demonstrate a high titer of hepatitis B antibody 
D)  None of the above 
A)  Recombinant hepatitis B purified protein 
B)  Plasma donors whose sera are devoid of hepatitis B antibody 
C)  Plasma donors whose sera demonstrate a high titer of hepatitis B antibody 
D)  None of the above

Question 8

A patient with hypofibrinogenemia is receiving cryoprecipitate on an outpatient basis. His plasma volume is 4,000 mL, and his physician wants to increase factor I from 40 mg/dL to 120 mg/dL. How many bags of cryoprecipitate are needed?

Accepted Answer

A)  8 
B)  13 
C)  15 
D)  21 
A)  8 
B)  13 
C)  15 
D)  21

Question 9

What disease state may require exogenous fibrinogen replacement?

Accepted Answer

A)  Disseminated intravascular coagulation 
B)  Liver failure 
C)  Congenital fibrinogen deficiency 
D)  All of the above 
A)  Disseminated intravascular coagulation 
B)  Liver failure 
C)  Congenital fibrinogen deficiency 
D)  All of the above

Question 10

What is suspected when the hematocrit has decreased by 4% and the total bilirubin level is increased 5 days after transfusion?

Accepted Answer

A)  Acute hemolytic transfusion reaction 
B)  Volume overload 
C)  Delayed hemolytic transfusion reaction 
D)  Urticarial reaction 
A)  Acute hemolytic transfusion reaction 
B)  Volume overload 
C)  Delayed hemolytic transfusion reaction 
D)  Urticarial reaction

Question 11

Factor VIII is treated by which of the following to ensure sterility for HIV and hepatitis B and C?

Accepted Answer

A)  Pasteurization 
B)  Nanofiltration 
C)  Solvent detergent 
D)  All of the above 
A)  Pasteurization 
B)  Nanofiltration 
C)  Solvent detergent 
D)  All of the above

Question 12

What is the corrected platelet increment for a patient with a body surface area of 2.7 m2, an initial count of 15,000 per µL, and a 1-hour post-transfusion platelet count of 80,000 per µL given one apheresed platelet component?

Accepted Answer

A)  53,182 per µL 
B)  58,500 per µL 
C)  31,900 per µL 
D)  5,000 per µL 
A)  53,182 per µL 
B)  58,500 per µL 
C)  31,900 per µL 
D)  5,000 per µL

Question 13

Granulocytes for transfusion should:

Accepted Answer

A)  be administered through a microaggregate filter. 
B)  be ABO- and Rh-compatible with the recipient's serum. 
C)  be infused within 72 hours of collection. 
D)  never be transfused to patients with a history of febrile transfusion reaction. 
A)  be administered through a microaggregate filter. 
B)  be ABO- and Rh-compatible with the recipient's serum. 
C)  be infused within 72 hours of collection. 
D)  never be transfused to patients with a history of febrile transfusion reaction.

Question 14

How can GVHD be prevented in transplant recipients?

Accepted Answer

A)  Filtering of cellular components 
B)  Irradiation of cellular components 
C)  Deglycerolizing of cellular components 
D)  None of the above 
A)  Filtering of cellular components 
B)  Irradiation of cellular components 
C)  Deglycerolizing of cellular components 
D)  None of the above

Question 15

What is the advantage of performing a type and screen for patients scheduled for surgery instead of crossmatching units for possible transfusion?

Accepted Answer

A)  Increases the amount of crossmatch performed 
B)  Increases the availability of donor units in the inventory 
C)  Contributes to outdating of blood products 
D)  Decreases the number of panel studies done on positive antibody screens 
A)  Increases the amount of crossmatch performed 
B)  Increases the availability of donor units in the inventory 
C)  Contributes to outdating of blood products 
D)  Decreases the number of panel studies done on positive antibody screens

Question 16

Poor increment in the platelet count 1 hour following platelet transfusion is most commonly caused by:

Accepted Answer

A)  splenomegaly. 
B)  alloimmunization to HLA antigens. 
C)  disseminated intravascular coagulation. 
D)  defective platelets. 
A)  splenomegaly. 
B)  alloimmunization to HLA antigens. 
C)  disseminated intravascular coagulation. 
D)  defective platelets.

Question 17

Which of the following is an indication for immunoglobulin administration?

Accepted Answer

A)  Cytomegalovirus 
B)  Hepatitis A 
C)  Infectious mononucleosis 
D)  Congenital hypergammaglobulinemia 
A)  Cytomegalovirus 
B)  Hepatitis A 
C)  Infectious mononucleosis 
D)  Congenital hypergammaglobulinemia

Question 18

Which of the following factors are found in therapeutic levels in fresh frozen plasma?

Accepted Answer

A)  Factor VIII 
B)  Factor V 
C)  Factor XI 
D)  All of the above 
A)  Factor VIII 
B)  Factor V 
C)  Factor XI 
D)  All of the above

Question 19

Cryoprecipitated AHF can be used to treat von Willebrand's disease by providing _________vWF after _________has failed to release adequate amounts of endogenous vWF.

Accepted Answer

A)  exogenous/DDAVP 
B)  endogenous/DDAVP 
C)  exogenous/factor VIII concentrates 
D)  endogenous/factor VIII concentrates 
A)  exogenous/DDAVP 
B)  endogenous/DDAVP 
C)  exogenous/factor VIII concentrates 
D)  endogenous/factor VIII concentrates

Question 20

What is the immunologic principle of RhIG administration?

Accepted Answer

A)  Anti-D attaches to Rh-positive cells of mother and are subsequently removed by cells of the reticuloendothelial system, preventing sensitization. 
B)  Anti-D attaches to Rh-positive cells of the infant in maternal circulation and are subsequently removed by cells of the reticuloendothelial system, preventing sensitization. 
C)  Anti-D attaches to Rh-negative cells of the infant in maternal circulation and are subsequently removed by cells of the reticuloendothelial system, preventing sensitization. 
D)  None of the above 
A)  Anti-D attaches to Rh-positive cells of mother and are subsequently removed by cells of the reticuloendothelial system, preventing sensitization. 
B)  Anti-D attaches to Rh-positive cells of the infant in maternal circulation and are subsequently removed by cells of the reticuloendothelial system, preventing sensitization. 
C)  Anti-D attaches to Rh-negative cells of the infant in maternal circulation and are subsequently removed by cells of the reticuloendothelial system, preventing sensitization. 
D)  None of the above

Exam 15: Transfusion Therapy

Leukoreduction filters are used in the transfusion of red blood cells and platelets to prevent:

Oncology patients usually receive repeated red blood cell and platelet transfusions because of:

Why are fresh blood units (less than 7 days old) preferred for a neonate transfusion?

How does 25% albumin induce diuresis in liver disease patients?

Which of the following methods provides the purest factor VIII concentrates?

All coagulation factors are produced in the liver except:

What is the source of hyperimmune globulins used in the prevention of hepatitis B?

A patient with hypofibrinogenemia is receiving cryoprecipitate on an outpatient basis. His plasma volume is 4,000 mL, and his physician wants to increase factor I from 40 mg/dL to 120 mg/dL. How many bags of cryoprecipitate are needed?

What disease state may require exogenous fibrinogen replacement?

What is suspected when the hematocrit has decreased by 4% and the total bilirubin level is increased 5 days after transfusion?

Factor VIII is treated by which of the following to ensure sterility for HIV and hepatitis B and C?

What is the corrected platelet increment for a patient with a body surface area of 2.7 m2, an initial count of 15,000 per µL, and a 1-hour post-transfusion platelet count of 80,000 per µL given one apheresed platelet component?

Granulocytes for transfusion should:

How can GVHD be prevented in transplant recipients?

What is the advantage of performing a type and screen for patients scheduled for surgery instead of crossmatching units for possible transfusion?

Poor increment in the platelet count 1 hour following platelet transfusion is most commonly caused by:

Which of the following is an indication for immunoglobulin administration?

Which of the following factors are found in therapeutic levels in fresh frozen plasma?

Cryoprecipitated AHF can be used to treat von Willebrand's disease by providing _________vWF after _________has failed to release adequate amounts of endogenous vWF.

What is the immunologic principle of RhIG administration?

Red Blood Cells and Platelet Preservation: Historical Perspectives and Current Trends

Basic Genetics

Fundamentals of Immunology

Concepts in Molecular Biology

The Antiglobulin Test

The Abo Blood Group System

The RH Blood Group System

Blood Group Terminology and the Other Blood Groups

Detection and Identification of Antibodies

Pre-Transfusion Testing

Overview of the Routine Blood Bank Laboratory

Other Technologies and Automation

Donor Screening and Component Preparation

Apheresis

Cellular Therapy

Transfusion-Transmitted Diseases

Hemolytic Disease of the Fetus and Newborn

Autoimmune Hemolytic Anemias

The Hla System

Relationship Testing

Quality Management

Transfusion Safety and Federal Regulatory Requirements

Utilization Management

Laboratory Information Systems

Medicolegal and Ethical Aspects of Providing Blood Collection and Transfusion Services

Tissue Banking: A New Role for the Transfusion Service

Filters

What is the corrected platelet increment for a patient with a body surface area of 2.7 m², an initial count of 15,000 per µL, and a 1-hour post-transfusion platelet count of 80,000 per µL given one apheresed platelet component?

Cryoprecipitated AHF can be used to treat von Willebrand's disease by providing _vWF after _has failed to release adequate amounts of endogenous vWF.